Loading
Life sciences · Journal article
Marine Drugs · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Phloroglucinol (PG) is a naturally occurring phenolic compound and the fundamental monomeric unit of marine phlorotannins, yet its effects on adipocyte differentiation and browning remain incompletely understood. This study investigated whether PG inhibits adipogenesis and induces browning markers in 3T3-L1 adipocytes through Nrf2/HO-1 pathway activation. Differentiating 3T3-L1 cells were treated with PG (10, 50, and 100 µM) with or without ZnPP (5 µM), a specific HO-1 inhibitor. PG concentration-dependently reduced lipid accumulation and intracellular cholesterol and triglyceride levels, while suppressing PPARγ, C/EBPα, FAS, and aP2 protein expression. PG also upregulated the browning markers UCP1, PGC-1α, and PRDM16, and activated AMPK. Mechanistically, PG promoted Nrf2 nuclear translocation and increased HO-1 expression, accompanied by reduced ROS production and enhanced SOD, GPx, and CAT activities. Notably, ZnPP co-treatment reversed all these effects—lipid accumulation returned toward control levels, adipogenic markers increased, browning markers decreased, and antioxidant enzyme activities were attenuated—while Nrf2 nuclear translocation and HO-1 protein expression remained elevated. These findings demonstrate that PG inhibits adipogenesis and induces browning markers through an HO-1-dependent mechanism, with ZnPP experiments confirming that HO-1 activity is functionally required for these effects. This is the first study to establish a causal link between Nrf2/HO-1 activation and the anti-adipogenic effects and browning marker upregulation of PG in adipocytes. Given PG’s established safety profile as an approved antispasmodic agent, these findings support its potential as a multi-target therapeutic candidate for obesity and related metabolic disorders.